Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bayer Aktienges ADR (OP: BAYRY )

8.505 +0.145 (+1.73%)
Streaming Delayed Price Updated: 3:29 PM EST, Nov 30, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,480,840
Open 8.500
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 8.360
Today's Range 8.430 - 8.530
52wk Range 8.310 - 17.00
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
PFAS's Forever Problem: Ohio Lawsuit Against Chemical Companies Fizzles Out
Big chemical companies won a lawsuit preventing 11.8 million Ohio residents from suing them for PFAS chemicals in their blood. 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
3 Battered Blue-Chip Stocks to Sell in December
Steer clear of these once flourishing companies, each of which has problems they need to overcome before their share price rises again. 
Via InvestorPlace

Performance

YTD
-34.68%
-34.68%
1 Month
-21.25%
-21.25%
3 Month
-38.19%
-38.19%
6 Month
-39.16%
-39.16%
1 Year
-41.51%
-41.51%

More News

Read More
German Conglomerate Bayer Faces Investor Scrutiny Amid Unexpected Legal, Trial Setbacks
Via Benzinga
Analyst Assess Implications of Bristol Myers' Investigational Blood Thinner Post Bayer Trial Setback Amid Shaken Investor Confidence
Via Benzinga
Bayer's Blood Thinner Study Stopped Early Due To Lack Of Efficacy: Details
Via Benzinga
Bayer's Legal Victory Against Merck: Delaware Court Rules In Company's Favor Regarding Talc Lawsuits
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Bayer CEO Resists Full Tri-Split, German Conglomerate Cuts Management Jobs In The Face Of Q3 Loss
Via Benzinga
Earnings Review: Bayer To Make Strategic Changes After Q3 Results
Via Talk Markets
Legal Woes Mount for Bayer As Roundup Weed Killer-Related Cancer Cases Continue, Faces Third Trial Loss
Via Benzinga
Exposures Glyphosate
Cathie Wood’s Stock Shuffle: 4 Names She’s Loving, 3 She’s Leaving
Via InvestorPlace
AI To Revolutionize Clinical Trials And Diagnostics
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
From Years to Months: How AI is Shaping the Landscape of Clinical Trials
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
FDA Panel Says Popular OTC Cold, Allergy Medicine Might Be Useless - Stocks To Watch
Via Benzinga
Exposures Product Safety
Hawaiian Electric Says Power Lines Not Responsible For Deadly Lahaina Fire, China Targets Stock Market Revival, FTC Pauses Legal Battle With Amgen's $28B Horizon Deal: Today's Top Stories
Via Benzinga
German Pharma Firm Bayer's New Parkinson's Treatment Shows Promise: What the Phase 1 Trial Reveals
Via Benzinga
FDA Approves Regeneron Pharmaceuticals' Higher Dose Of Eylea For Age-Related Blindness
Via Benzinga
Exposures Product Safety
As Tiziana Life Sciences (NASDAQ: TLSA) Prepares For Phase 2 Trials, Have They Successfully Derisked Foralumab?
Via Benzinga
Regeneron Pharma Says Fewer Aflibercept Injections Maintains Vision, Anatomic Improvements In Diabetic Macular Edema
Via Benzinga
Phase 1 Results Are "Extraordinary," Says Chairman Of Scientific Advisory Board As Biomedical Company Preps Phase 2 Trial For MS Treatment
Via Benzinga
AstraZeneca's Imfinzi/Imjudo Combo Shows Sustained Overall Survival Benefit At Four Years In Liver Cancer
Via Benzinga
Bayers Says Neuronal Stem Cell Therapy For Parkinson's Shows Encouraging Action In Early-Stage Study
Via Benzinga
Experimental Stem Cell Therapy For Parkinson's Shows Promise in Phase I Trial: Reuters
Via Benzinga
Regeneron Stock Crumbles After FDA Rejects Its Next Blockbuster Contender
Via Investor's Business Daily
Fusion Pharmaceuticals is Future Pillar of Cancer Treatment: Analyst
Via Benzinga
Unmasking Q2 2023's Stars & Strugglers: Industry ETFs And Top Stock Standouts
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.